Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $19 price target. Taysha Gene Therapies, Inc. (TSHA) Making Progress on Crucial Rett Syndrome Treatment Pressmaster/Shutterstock.com The positive stance is in response to the company making significant progress on the development of TSHA-102, an investigational gene transfer therapy in evaluation for Rett syndrome. Chief Executive Officer Sean Noland has already confirmed they are bolstering commercial-readiness efforts ahead of potential registration. Taysha Gene Therapies has also received FDA clearance to initiate the ASPIRE trial in 3 patients to support a potential broad label in the second quarter. The milestone follows a favorable tolerability profile, continued patient enrollment, and a well-defined regulatory trajectory. Amid TSHA-102 development progress, Taysha Gene Therapies reported a net loss of $109 million, or $0.34 per share, for the year ended December 31, 2025. It was a significant increase fr
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies (TSHA) had its price target raised by Canaccord Genuity Group Inc. from $14.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies (TSHA) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Taysha Gene Therapies (TSHA) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
TSHA
Earnings
- 3/19/26 - Miss
TSHA
Sec Filings
- 4/13/26 - Form 4
- 4/10/26 - Form 144
- 3/19/26 - Form 10-K
- TSHA's page on the SEC website